Cargando…

An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer

BACKGROUND: The head and neck cancer (HNC) Patient Concerns Inventory (PCI) is a condition-specific prompt list that allows patients to raise concerns to cancer consultants that otherwise might be overlooked. OBJECTIVE: This is the first economic evaluation of the PCI in patients with HNC investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezeofor, Victory ‘Segun, Spencer, Llinos Haf, Rogers, Simon N., Kanatas, Anastasios, Lowe, Derek, Semple, Cherith J., Hanna, Jeffrey R., Yeo, Seow Tien, Edwards, Rhiannon Tudor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802252/
https://www.ncbi.nlm.nih.gov/pubmed/35099783
http://dx.doi.org/10.1007/s41669-021-00320-4
_version_ 1784642641154015232
author Ezeofor, Victory ‘Segun
Spencer, Llinos Haf
Rogers, Simon N.
Kanatas, Anastasios
Lowe, Derek
Semple, Cherith J.
Hanna, Jeffrey R.
Yeo, Seow Tien
Edwards, Rhiannon Tudor
author_facet Ezeofor, Victory ‘Segun
Spencer, Llinos Haf
Rogers, Simon N.
Kanatas, Anastasios
Lowe, Derek
Semple, Cherith J.
Hanna, Jeffrey R.
Yeo, Seow Tien
Edwards, Rhiannon Tudor
author_sort Ezeofor, Victory ‘Segun
collection PubMed
description BACKGROUND: The head and neck cancer (HNC) Patient Concerns Inventory (PCI) is a condition-specific prompt list that allows patients to raise concerns to cancer consultants that otherwise might be overlooked. OBJECTIVE: This is the first economic evaluation of the PCI in patients with HNC investigating the costs and effects to the health service of not prioritising certain treatment pathways in addition to the primary cancer pathway. Additional costs can be accrued due to delayed referral to other appropriate services, e.g. hospital dentist. Economic evidence could influence future policy direction in this area globally. METHODS: Alongside a 3-year clustered randomised controlled trial, an economic evaluation was undertaken with Client Service Receipt Inventory data collected at three different time points (baseline and 6 and 12 months post-baseline). Patients were identified by a multidisciplinary team at the trial clinics. This economic analysis compared the PCI intervention versus the non-PCI treatment pathway. A deterministic and probabilistic sensitivity analysis was conducted to investigate the cost per quality-adjusted life-year (QALY) gain of the PCI versus non-PCI intervention treatment pathways. Qualitative data were also collected from seven consultants to triangulate findings from the economic evaluation. RESULTS: The analysis used data from 191 patients (66% of the full trial sample). The PCI inventory was low cost, at just over £13 per participant. The PCI intervention was cost effective and also cost saving, with an incremental cost difference of £295.91 over the 12-month follow-up period. The QALY values were higher in the PCI intervention strategy, with a value of 0.79, whereas the non-PCI group had a value of 0.76, thus the PCI intervention was dominant. The sensitivity analysis showed that, at a willingness-to-pay threshold of £20,000 per QALY gained, the probability of being cost effective was 0.85 (95% confidence interval [CI] 0.80–0.83). Qualitative results showed that consultants using the PCI reported an enhanced awareness of patients’ overall post-treatment needs. DISCUSSION: The PCI provided an effective means to conduct clinical consultations by avoiding unnecessary healthcare costs and focussing on aspects of care most important to patients. The cost per QALY gain was within the National Institute for Health and Care Excellence guideline threshold. The economic evaluation showed that the PCI intervention strategy was dominant and therefore cost saving to the national health service (NHS) and was more effective in terms of treatment. CONCLUSION: The PCI appears to be a low-cost intervention that generates a cost-effective benefit to patients from a NHS perspective if rolled out as part of routine care. Qualitative evidence has shown that the use of the PCI is supported by consultants in routine practice. TRIAL REGISTRATION: Clinical Trials Identifier: NCT03086629. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00320-4.
format Online
Article
Text
id pubmed-8802252
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88022522022-01-31 An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer Ezeofor, Victory ‘Segun Spencer, Llinos Haf Rogers, Simon N. Kanatas, Anastasios Lowe, Derek Semple, Cherith J. Hanna, Jeffrey R. Yeo, Seow Tien Edwards, Rhiannon Tudor Pharmacoecon Open Original Research Article BACKGROUND: The head and neck cancer (HNC) Patient Concerns Inventory (PCI) is a condition-specific prompt list that allows patients to raise concerns to cancer consultants that otherwise might be overlooked. OBJECTIVE: This is the first economic evaluation of the PCI in patients with HNC investigating the costs and effects to the health service of not prioritising certain treatment pathways in addition to the primary cancer pathway. Additional costs can be accrued due to delayed referral to other appropriate services, e.g. hospital dentist. Economic evidence could influence future policy direction in this area globally. METHODS: Alongside a 3-year clustered randomised controlled trial, an economic evaluation was undertaken with Client Service Receipt Inventory data collected at three different time points (baseline and 6 and 12 months post-baseline). Patients were identified by a multidisciplinary team at the trial clinics. This economic analysis compared the PCI intervention versus the non-PCI treatment pathway. A deterministic and probabilistic sensitivity analysis was conducted to investigate the cost per quality-adjusted life-year (QALY) gain of the PCI versus non-PCI intervention treatment pathways. Qualitative data were also collected from seven consultants to triangulate findings from the economic evaluation. RESULTS: The analysis used data from 191 patients (66% of the full trial sample). The PCI inventory was low cost, at just over £13 per participant. The PCI intervention was cost effective and also cost saving, with an incremental cost difference of £295.91 over the 12-month follow-up period. The QALY values were higher in the PCI intervention strategy, with a value of 0.79, whereas the non-PCI group had a value of 0.76, thus the PCI intervention was dominant. The sensitivity analysis showed that, at a willingness-to-pay threshold of £20,000 per QALY gained, the probability of being cost effective was 0.85 (95% confidence interval [CI] 0.80–0.83). Qualitative results showed that consultants using the PCI reported an enhanced awareness of patients’ overall post-treatment needs. DISCUSSION: The PCI provided an effective means to conduct clinical consultations by avoiding unnecessary healthcare costs and focussing on aspects of care most important to patients. The cost per QALY gain was within the National Institute for Health and Care Excellence guideline threshold. The economic evaluation showed that the PCI intervention strategy was dominant and therefore cost saving to the national health service (NHS) and was more effective in terms of treatment. CONCLUSION: The PCI appears to be a low-cost intervention that generates a cost-effective benefit to patients from a NHS perspective if rolled out as part of routine care. Qualitative evidence has shown that the use of the PCI is supported by consultants in routine practice. TRIAL REGISTRATION: Clinical Trials Identifier: NCT03086629. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00320-4. Springer International Publishing 2022-01-31 /pmc/articles/PMC8802252/ /pubmed/35099783 http://dx.doi.org/10.1007/s41669-021-00320-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Ezeofor, Victory ‘Segun
Spencer, Llinos Haf
Rogers, Simon N.
Kanatas, Anastasios
Lowe, Derek
Semple, Cherith J.
Hanna, Jeffrey R.
Yeo, Seow Tien
Edwards, Rhiannon Tudor
An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title_full An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title_fullStr An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title_full_unstemmed An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title_short An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
title_sort economic evaluation supported by qualitative data about the patient concerns inventory (pci) versus standard treatment pathway in the management of patients with head and neck cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802252/
https://www.ncbi.nlm.nih.gov/pubmed/35099783
http://dx.doi.org/10.1007/s41669-021-00320-4
work_keys_str_mv AT ezeoforvictorysegun aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT spencerllinoshaf aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT rogerssimonn aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT kanatasanastasios aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT lowederek aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT semplecherithj aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT hannajeffreyr aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT yeoseowtien aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT edwardsrhiannontudor aneconomicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT ezeoforvictorysegun economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT spencerllinoshaf economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT rogerssimonn economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT kanatasanastasios economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT lowederek economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT semplecherithj economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT hannajeffreyr economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT yeoseowtien economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer
AT edwardsrhiannontudor economicevaluationsupportedbyqualitativedataaboutthepatientconcernsinventorypciversusstandardtreatmentpathwayinthemanagementofpatientswithheadandneckcancer